Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.

Laschanzky RS, Humphrey LE, Ma J, Smith LM, Enke TJ, Shukla SK, Dasgupta A, Singh PK, Howell GM, Brattain MG, Ly QP, Black AR, Black JD.

Cancers (Basel). 2019 Sep 7;11(9). pii: E1327. doi: 10.3390/cancers11091327.

2.

TGFβ and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells.

Leiphrakpam PD, Brattain MG, Black JD, Wang J.

J Biol Chem. 2018 May 25;293(21):8242-8254. doi: 10.1074/jbc.RA117.001299. Epub 2018 Mar 29.

3.

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.

Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, Brattain MG, Natarajan A.

Oncotarget. 2017 Dec 28;9(4):5216-5232. doi: 10.18632/oncotarget.23749. eCollection 2018 Jan 12.

4.

TGFβ/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells.

Bailey KL, Agarwal E, Chowdhury S, Luo J, Brattain MG, Black JD, Wang J.

PLoS One. 2017 Apr 17;12(4):e0176096. doi: 10.1371/journal.pone.0176096. eCollection 2017.

5.

Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.

Agarwal E, Robb CM, Smith LM, Brattain MG, Wang J, Black JD, Chowdhury S.

Oncogene. 2017 Jun 1;36(22):3104-3118. doi: 10.1038/onc.2016.460. Epub 2017 Jan 9.

6.

AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival.

Fisher KW, Das B, Kim HS, Clymer BK, Gehring D, Smith DR, Costanzo-Garvey DL, Fernandez MR, Brattain MG, Kelly DL, MacMillan J, White MA, Lewis RE.

Mol Cell Biol. 2015 Nov;35(22):3866-79. doi: 10.1128/MCB.00528-15. Epub 2015 Sep 8.

7.

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.

Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S.

BMC Cancer. 2014 Mar 1;14:145. doi: 10.1186/1471-2407-14-145.

8.

Ezrin expression and cell survival regulation in colorectal cancer.

Leiphrakpam PD, Rajput A, Mathiesen M, Agarwal E, Lazenby AJ, Are C, Brattain MG, Chowdhury S.

Cell Signal. 2014 May;26(5):868-79. doi: 10.1016/j.cellsig.2014.01.014. Epub 2014 Jan 22.

9.

In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.

Leiphrakpam PD, Agarwal E, Mathiesen M, Haferbier KL, Brattain MG, Chowdhury S.

Oncol Rep. 2014 Jan;31(1):87-94. doi: 10.3892/or.2013.2819. Epub 2013 Oct 25.

10.

Differential PKA activation and AKAP association determines cell fate in cancer cells.

Hedrick ED, Agarwal E, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S.

J Mol Signal. 2013 Oct 1;8(1):10. doi: 10.1186/1750-2187-8-10.

11.

Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).

Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG.

PLoS One. 2013 Jul 29;8(7):e69992. doi: 10.1371/journal.pone.0069992. Print 2013.

12.

Restoration of PTEN activity decreases metastases in an orthotopic model of colon cancer.

Chowdhury S, Ongchin M, Wan G, Sharratt E, Brattain MG, Rajput A.

J Surg Res. 2013 Oct;184(2):755-60. doi: 10.1016/j.jss.2013.03.035. Epub 2013 Apr 6.

13.

Cell survival and metastasis regulation by Akt signaling in colorectal cancer.

Agarwal E, Brattain MG, Chowdhury S.

Cell Signal. 2013 Aug;25(8):1711-9. doi: 10.1016/j.cellsig.2013.03.025. Epub 2013 Apr 18. Review.

14.

Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines.

Chowdhury S, Ongchin M, Sharratt E, Dominguez I, Wang J, Brattain MG, Rajput A.

PLoS One. 2013;8(4):e60299. doi: 10.1371/journal.pone.0060299. Epub 2013 Apr 1.

15.

Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer.

Rajput A, Agarwal E, Leiphrakpam P, Brattain MG, Chowdhury S.

ISRN Hepatol. 2013 Apr 21;2013:206875. doi: 10.1155/2013/206875. eCollection 2013.

16.

N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα).

Sabbah DA, Simms NA, Wang W, Dong Y, Ezell EL, Brattain MG, Vennerstrom JL, Zhong HA.

Bioorg Med Chem. 2012 Dec 15;20(24):7175-83. doi: 10.1016/j.bmc.2012.09.059. Epub 2012 Oct 12.

PMID:
23121722
17.

Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, Li F.

Int J Biochem Mol Biol. 2012;3(2):179-97. Epub 2012 May 18.

18.

Transforming growth factor-β suppresses metastasis in a subset of human colon carcinoma cells.

Simms NA, Rajput A, Sharratt EA, Ongchin M, Teggart CA, Wang J, Brattain MG.

BMC Cancer. 2012 Jun 6;12:221. doi: 10.1186/1471-2407-12-221.

19.

Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.

Sabbah DA, Simms NA, Brattain MG, Vennerstrom JL, Zhong H.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):876-80. doi: 10.1016/j.bmcl.2011.12.044. Epub 2011 Dec 13.

20.

Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

Sabbah DA, Brattain MG, Zhong H.

Curr Med Chem. 2011;18(36):5528-44. Review.

PMID:
22172063
21.

Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Chowdhury S, Howell GM, Teggart CA, Chowdhury A, Person JJ, Bowers DM, Brattain MG.

J Biol Chem. 2011 Sep 2;286(35):30937-48. doi: 10.1074/jbc.M110.212035. Epub 2011 Jul 8.

22.

Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer.

Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, Weber HR, Chowdhury A, Brattain MG.

PLoS One. 2011 May 3;6(5):e19335. doi: 10.1371/journal.pone.0019335.

23.

Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG.

J Biol Chem. 2009 Apr 17;284(16):10912-22. doi: 10.1074/jbc.M809551200. Epub 2009 Feb 18.

24.

A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling.

Sawhney RS, Liu W, Brattain MG.

J Cell Physiol. 2009 Apr;219(1):152-61. doi: 10.1002/jcp.21662.

PMID:
19089993
25.

Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG.

Cancer Res. 2008 Oct 1;68(19):8004-13. doi: 10.1158/0008-5472.CAN-08-0280.

26.

Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.

Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG.

Cancer Res. 2008 May 1;68(9):3152-60. doi: 10.1158/0008-5472.CAN-07-5348.

27.

Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation.

Spengler ML, Guo LW, Brattain MG.

Cell Cycle. 2008 Mar 1;7(5):623-30. Epub 2007 Dec 4.

PMID:
18239466
28.

Characterization of HCT116 human colon cancer cells in an orthotopic model.

Rajput A, Dominguez San Martin I, Rose R, Beko A, Levea C, Sharratt E, Mazurchuk R, Hoffman RM, Brattain MG, Wang J.

J Surg Res. 2008 Jun 15;147(2):276-81. Epub 2007 Oct 24.

PMID:
17961596
29.

The maximal size of protein to diffuse through the nuclear pore is larger than 60kDa.

Wang R, Brattain MG.

FEBS Lett. 2007 Jul 10;581(17):3164-70. Epub 2007 Jun 12.

30.

Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.

Guo XN, Rajput A, Rose R, Hauser J, Beko A, Kuropatwinski K, LeVea C, Hoffman RM, Brattain MG, Wang J.

Cancer Res. 2007 Jun 15;67(12):5851-8.

31.

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A, Kan JL, Gibson NW, Willson JK, Cowell JK, Brattain MG.

Mol Cancer Ther. 2007 Mar;6(3):1143-50.

32.

A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.

Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS.

Clin Cancer Res. 2007 Feb 15;13(4):1216-23.

33.

A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG.

Cancer Res. 2007 Jan 15;67(2):665-73.

34.

Akt expression may predict favorable prognosis in cholangiocarcinoma.

Javle MM, Yu J, Khoury T, Chadha KS, Iyer RV, Foster J, Kuvshinoff BW, Gibbs JF, Geradts J, Black JD, Brattain MG.

J Gastroenterol Hepatol. 2006 Nov;21(11):1744-51. Erratum in: J Gastroenterol Hepatol. 2007 Jan;22(1):145. Chadha, Krishdeep C [corrected to Chadha, Krishdeep S].

PMID:
16984600
35.

Role of the Survivin gene in pathophysiology.

Li F, Brattain MG.

Am J Pathol. 2006 Jul;169(1):1-11. Review.

36.

Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma.

Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM.

Ann Surg Oncol. 2006 Jul;13(7):933-9. Epub 2006 May 22.

PMID:
16788754
37.

AKT can be activated in the nucleus.

Wang R, Brattain MG.

Cell Signal. 2006 Oct;18(10):1722-31. Epub 2006 Feb 28.

PMID:
16616456
38.
39.

Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription.

Spengler ML, Brattain MG.

J Biol Chem. 2006 Mar 3;281(9):5567-74. Epub 2006 Jan 5.

40.

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.

Cancer Res. 2006 Jan 1;66(1):404-11.

42.

Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells.

Hu YP, Venkateswarlu S, Sergina N, Howell G, St Clair P, Humphrey LE, Li W, Hauser J, Zborowska E, Willson JK, Brattain MG.

J Biol Chem. 2005 Jul 22;280(29):27383-92. Epub 2005 May 11.

43.

Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines.

Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG.

Oncogene. 2005 Feb 17;24(8):1385-95.

44.

Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.

Spengler ML, Kennett SB, Moorefield KS, Simmons SO, Brattain MG, Horowitz JM.

Cell Signal. 2005 Feb;17(2):153-66.

PMID:
15494207
45.

Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells.

Sawhney RS, Cookson MM, Sharma B, Hauser J, Brattain MG.

J Biol Chem. 2004 Nov 5;279(45):47379-90. Epub 2004 Aug 10.

46.

Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity.

Wang J, Sergina N, Ko TC, Gong J, Brattain MG.

J Biol Chem. 2004 Sep 17;279(38):40237-44. Epub 2004 Jul 22.

47.
49.

Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.

Ammanamanchi S, Tillekeratne MP, Ko TC, Brattain MG.

Cancer Res. 2004 Apr 1;64(7):2509-15.

50.

ErbB family targeting.

Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK.

Curr Opin Investig Drugs. 2003 Dec;4(12):1451-4. Review.

PMID:
14763131

Supplemental Content

Loading ...
Support Center